GlassScriptPhysician profile
Michael Joseph Ward
NPI 1609919406
$3,440.27
in general payments reported to CMS, 2019-2025
23 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $36.23 · 2021: $331 · 2022: $554 · 2023: $788 · 2024: $790 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $707.35 | 2019-2024 | Eylea, Eylea Hd |
| Alimera Sciences, INC. | $627.44 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $323.18 | 2019-2025 | Vabysmo |
| Alcon Vision LLC | $285.31 | 2023-2025 | Clareon Panoptix Pro, Unity, Clareon |
| Abbvie INC. | $225.74 | 2022-2025 | Ozurdex |
| Eyepoint US, INC. | $189.72 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $147.65 | 2019-2021 | |
| Allergan, INC. | $129.79 | 2019-2021 | |
| Oyster Point Pharma, INC. | $118.38 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $112.60 | 2019-2024 | |
| Biogen, INC. | $100.00 | 2023 | |
| Genentech, INC. | $69.31 | 2021-2024 | Vabysmo |
| Harrow Eye, LLC | $64.80 | 2024-2025 | Vevye |
| Ani Pharmaceuticals, INC. | $63.72 | 2025 | Iluvien |
| Bausch & Lomb Americas INC. | $52.84 | 2022-2024 | Xipere, Xiidra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.19 | 2019-2021 | |
| Astellas Pharma US INC | $43.54 | 2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $26.60 | 2019-2021 | |
| Medtronic, INC. | $22.58 | 2024 | Dextile |
| Rayner Intraocular Lenses Limited | $21.19 | 2023 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Kala Pharmaceuticals, INC. | $20.00 | 2019 | |
| Biotissue Holdings INC. | $19.90 | 2022 | |
| Eyevance Pharmaceuticals LLC | $19.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.